Healios KK (JP:4593) has released an update.
Healios KK has announced an extension of their deadline for a definitive agreement with Nobelpharma Co., Ltd. regarding the development and commercialization of MultiStem for ARDS treatment in Japan, now set for the end of September 2024. This extension is to align their development strategy with upcoming discussions with the FDA for a global phase III clinical trial. The company highlights that this extension does not impact their consolidated financial results for the fiscal year ending December 31, 2024.
For further insights into JP:4593 stock, check out TipRanks’ Stock Analysis page.
